| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624215P | 2012-04-13 | 2012-04-13 |
| Publication Number | Publication Date |
|---|---|
| SG10201608577RAtrue SG10201608577RA (en) | 2016-12-29 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201608577RASG10201608577RA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG10201912109QASG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG11201406468YASG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912109QASG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG11201406468YASG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| Country | Link |
|---|---|
| US (7) | US9394283B2 (en) |
| EP (4) | EP3184523B1 (en) |
| JP (3) | JP6255382B2 (en) |
| KR (4) | KR102744039B1 (en) |
| CN (2) | CN104603130B (en) |
| AU (2) | AU2013245878B2 (en) |
| BR (1) | BR112014025508B1 (en) |
| CA (1) | CA2870005C (en) |
| CY (2) | CY1119383T1 (en) |
| DK (3) | DK3628670T3 (en) |
| ES (3) | ES2617379T3 (en) |
| HR (2) | HRP20170295T1 (en) |
| HU (3) | HUE060881T2 (en) |
| IL (4) | IL296199B2 (en) |
| IN (1) | IN2014DN09068A (en) |
| LT (2) | LT3184523T (en) |
| MX (2) | MX384641B (en) |
| NZ (1) | NZ700761A (en) |
| PL (3) | PL3628670T3 (en) |
| PT (3) | PT3184523T (en) |
| RS (2) | RS59392B1 (en) |
| RU (1) | RU2658911C2 (en) |
| SG (3) | SG10201608577RA (en) |
| SI (2) | SI2836491T1 (en) |
| SM (2) | SMT201900501T1 (en) |
| WO (1) | WO2013155317A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Heteroaryl or aryl substituted gasoline compounds |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SG10201608577RA (en)* | 2012-04-13 | 2016-12-29 | Epizyme Inc | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| MX392752B (en) | 2012-04-13 | 2025-03-24 | Epizyme Inc | COMBINATION THERAPY TO TREAT CANCER. |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| PT2908823T (en)* | 2012-10-15 | 2019-11-04 | Epizyme Inc | Methods of treating cancer |
| US9006242B2 (en)* | 2012-10-15 | 2015-04-14 | Epizyme, Inc. | Substituted benzene compounds |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2014177982A1 (en) | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| CA2917463A1 (en) | 2013-07-10 | 2015-01-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| PL3057962T3 (en) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
| EP3057594A4 (en)* | 2013-10-18 | 2017-06-07 | Epizyme, Inc. | Method of treating cancer |
| WO2015077193A1 (en)* | 2013-11-19 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| WO2015085325A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| KR20230031963A (en) | 2014-06-17 | 2023-03-07 | 에피자임, 인코포레이티드 | Ezh2 inhibitors for treating lymphoma |
| CA2952830C (en) | 2014-06-20 | 2022-11-01 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| CA2963149A1 (en) | 2014-10-16 | 2016-04-21 | Epizyme, Inc. | Method for treating cancer |
| WO2016081523A1 (en) | 2014-11-17 | 2016-05-26 | Epizyme, Inc. | Method for treating cancer |
| TW201636344A (en) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Inhibitors of EZH2 |
| SG11201708286PA (en) | 2015-04-20 | 2017-11-29 | Epizyme Inc | Combination therapy for treating cancer |
| AU2016275051A1 (en) | 2015-06-10 | 2017-12-07 | Epizyme, Inc. | EZH2 inhibitors for treating lymphoma |
| IL307260A (en) | 2015-08-24 | 2023-11-01 | Epizyme Inc | A method for treating cancer |
| TW201718598A (en) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | Combination therapy for treating cancer |
| EP3464643A4 (en) | 2016-06-01 | 2020-04-01 | Epizyme Inc | USE OF EZH2 INHIBITORS FOR TREATING CANCER |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| CA3039059A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| WO2018137639A1 (en)* | 2017-01-25 | 2018-08-02 | 恩瑞生物医药科技（上海）有限公司 | Histone methyltransferase ezh2 inhibitor, preparation method and pharmaceutical use thereof |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN110944628A (en) | 2017-06-02 | 2020-03-31 | Epizyme股份有限公司 | Treatment of cancer with EZH2 inhibitors |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | COMBINATION THERAPY FOR TREATMENT OF CANCER |
| JP2021531340A (en) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | Inhibition of the PRC2 subunit to treat eye disorders |
| CN114555112A (en) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | Combination therapy of T cell therapy and ZESTE enhancer homolog 2(EZH2) inhibitors and related methods |
| KR20220130698A (en)* | 2019-12-20 | 2022-09-27 | 에피자임, 인코포레이티드 | Crystalline hydrobromide salt of EZH2 inhibitor, preparation thereof and pharmaceutical composition useful for the treatment of cancer |
| WO2022208552A1 (en)* | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (en) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Process for producing N-cyano-N'-substituted-aryl carboximidamide compound |
| CA2155662A1 (en) | 1993-12-27 | 1995-07-06 | Fumihiro Ozaki | Anthranilic acid derivative |
| DE19516776A1 (en) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin regulatory genes |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (en) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N-substituted dioxothiazolidylbenzamide derivative and process for producing the same |
| WO2000018725A1 (en) | 1998-09-30 | 2000-04-06 | The Procter & Gamble Company | 2-substituted ketoamides |
| UA71587C2 (en) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Anthranilic acid amides and use thereof as medicaments |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| KR100828982B1 (en) | 2000-12-28 | 2008-05-14 | 시오노기세이야쿠가부시키가이샤 | Pyridone derivative having affinity for cannabinoid 2-type receptor |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| TW200303304A (en)* | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| PT1477186E (en) | 2002-02-19 | 2010-02-11 | Shionogi & Co | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| AU2005228899A1 (en) | 2004-03-30 | 2005-10-13 | Novartis Vaccines And Diagnostics, Inc. | Substituted thiophene derivatives as anti-cancer agents |
| JP5160885B2 (en) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Reconstituted histone methyltransferase complex and method for identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
| US7923219B2 (en) | 2005-06-02 | 2011-04-12 | The University Of North Carolina At Chapel Hill | Ubiquitin E3 ligase |
| FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
| AU2006303437B2 (en) | 2005-10-19 | 2012-06-28 | Grunenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
| NZ567000A (en) | 2005-10-21 | 2010-03-26 | Merck & Co Inc | Potassium channel inhibitors |
| CA2622615A1 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| MX2008014616A (en) | 2006-05-15 | 2008-11-28 | Irm Llc | Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors. |
| US20070287706A1 (en) | 2006-05-18 | 2007-12-13 | Dickson John K Jr | Certain substituted quinolones, compositions, and uses thereof |
| US8022246B2 (en) | 2006-10-10 | 2011-09-20 | The Burnham Institute For Medical Research | Neuroprotective compositions and methods |
| JP2010519204A (en) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | Nitrogen-containing heterocyclic ketones and their use as c-Met inhibitors |
| WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (en) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Novel vanilloid receptor ligands and their use in the preparation of medicines |
| WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| DE102007047737A1 (en)* | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidine and piperazine derivatives |
| WO2009058298A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
| CN101945869B (en) | 2007-12-19 | 2014-06-18 | 癌症研究技术有限公司 | Pyrido[2,3-B]pyrazine-8-substituted compounds and uses thereof |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| EP2323660A2 (en) | 2008-08-08 | 2011-05-25 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (en) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
| WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| CA2784899A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| UA110112C2 (en)* | 2010-05-07 | 2015-11-25 | Глаксосмітклайн Ллс | INDOLES |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| ES2534804T3 (en) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (en) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | METHODS TO DETECT WHETHER AN INDIVIDUAL IS A CANDIDATE FOR TREATMENT WITH OR RESPONSIVE TO AN EZH2 INHIBITOR AND THERAPEUTIC USES OF SUCH EZH2 INHIBITOR |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
| RU2013130253A (en) | 2010-12-03 | 2015-01-10 | Эпизайм, Инк. | 7-DEAZAPURINE HISTONIC METHYL TRANSFERASES AND WAYS OF THEIR APPLICATION |
| JP2014511389A (en) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (en) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | Substituted benzene compounds |
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Heteroaryl or aryl substituted gasoline compounds |
| ES2718900T3 (en) | 2012-03-12 | 2019-07-05 | Epizyme Inc | Human EZH2 inhibitors and methods of use thereof |
| SG10201608577RA (en)* | 2012-04-13 | 2016-12-29 | Epizyme Inc | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| MX392752B (en) | 2012-04-13 | 2025-03-24 | Epizyme Inc | COMBINATION THERAPY TO TREAT CANCER. |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| PT2908823T (en) | 2012-10-15 | 2019-11-04 | Epizyme Inc | Methods of treating cancer |
| PL3057962T3 (en) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
| Publication | Publication Date | Title |
|---|---|---|
| IL266165B (en) | Salt form of a human hi stone methyltransf erase ezh2 inhibitor | |
| IL259958B (en) | Heterocyclic inhibitors of glutaminase | |
| IL232599A (en) | Hydrobromide salt of pridopidine | |
| EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
| IL230901A0 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| ZA201401417B (en) | Novel soft rock inhibitors | |
| ZA201307496B (en) | Novel rock inhibitors | |
| IL232292A0 (en) | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | |
| PH12013502483A1 (en) | Use of a metal salt of 2-mercaptobenzothiazole | |
| EP2760853A4 (en) | Novel salts of alogliptin | |
| EP2709999A4 (en) | Quinazoline-7-ether compounds and methods of use | |
| GB201114854D0 (en) | Novel rock inhibitors | |
| PL2709584T3 (en) | Sensory use of 6-cyclopentylidenehexane derivatives | |
| GB201117252D0 (en) | Improved treatment of hard surfaces | |
| ZA201205358B (en) | Use of a salt of bistetrazolylamine | |
| ZA201308872B (en) | Use of a dinitromethane salt |